Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Consun Pharmaceutical GroupCPHGF +9.09%71 3-Year EBITDA Growth Rate is 11.70% as of Dec. 2025, which is at its 10-year median of 11.70. GuruFocus rates CPHGF with a GF Score™ of 71/100 and a GF Value™ of $1.13 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 809 Drug Manufacturers companies, Consun Pharmaceutical Group ranks better than 56.12% on this metric.
During the past 12 months, Consun Pharmaceutical Group's average EBITDA Per Share Growth Rate was 15.00% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 11.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 9.60% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 13.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Consun Pharmaceutical Group was 56.40% per year. The lowest was -16.10% per year. And the median was 11.70% per year.
Consun Pharmaceutical Group (OTCPK:CPHGF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Consun Pharmaceutical Group 3-Year EBITDA Growth Rate Related Terms
CPHGF vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Consun Pharmaceutical Group's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Consun Pharmaceutical Group 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Consun Pharmaceutical Group's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Consun Pharmaceutical Group's 3-Year EBITDA Growth Rate falls into.
Consun Pharmaceutical Group 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 11.70% mean?
Consun Pharmaceutical Group (CPHGF) has a 3-Year EBITDA Growth Rate of 11.70% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Consun Pharmaceutical Group and its competitors. This is near median its historical median of 11.70. According to the industry distribution chart, Consun Pharmaceutical Group ranks #355 out of 809 companies in the Drug Manufacturers industry, placing it in the top 43.9%.
Is Consun Pharmaceutical Group's 3-Year EBITDA Growth Rate too high?
Consun Pharmaceutical Group's current 3-Year EBITDA Growth Rate of 11.70% is near median its 10-year median of 11.70. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Consun Pharmaceutical Group's value of 11.70% is 31.5% above this industry median. Based on the distribution chart, Consun Pharmaceutical Group ranks #355 out of 809 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Consun Pharmaceutical Group has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Consun Pharmaceutical Group's 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Consun Pharmaceutical Group ranks #355 out of 809 companies for 3-Year EBITDA Growth Rate. This puts Consun Pharmaceutical Group in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. Consun Pharmaceutical Group's value of 11.70% is 31.5% above this benchmark. While the company's 10-year median is 11.70 vs. the industry median of 8.90, Consun Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Consun Pharmaceutical Group's current 3-Year EBITDA Growth Rate of 11.70% is 31.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Consun Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Consun Pharmaceutical Group's current 3-Year EBITDA Growth Rate is 11.70%, which is near median its own 10-year median of 11.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Consun Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Consun Pharmaceutical Group (CPHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.13, compared to a current price of $1.80 — trading 59.3% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 11.70%, which is near median its 10-year median of 11.70 and 31.5% above the Drug Manufacturers industry median of 8.90. Consun Pharmaceutical Group's overall GF Score™ is 71/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Consun Pharmaceutical Group (CPHGF), the current 3-Year EBITDA Growth Rate is 11.70% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Consun Pharmaceutical Group (CPHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Consun Pharmaceutical Group stock appears to be overvalued.
The current stock price of $1.80 is trading 59.3% above its estimated GF Value™ of $1.13.
GuruFocus considers Consun Pharmaceutical Group to be Significantly Overvalued.
Key valuation signals for CPHGF:
3-Year EBITDA Growth Rate: 11.70% (near median its 10-year median of 11.70)
GF Value™: $1.13 vs. price of $1.80 (59.3% above fair value)
Industry Position: 31.5% above the Drug Manufacturers median (#355 of 809)
No single metric tells the full story. See the CPHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Consun Pharmaceutical Group Ltd is a biotechnology company with a modern pharmaceutical enterprise that integrates R&D, production, and marketing. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Company derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
71GF Score
Get the complete analysis for CPHGF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPHGF has been successfully added to your 
